A 2D intestinal crypt platform for compound screens
Ended Project Grant Awarded Last action
- Award ID
- R44DK130647
- Recipient
-
Altis Biosystems, Inc. UEI YNJPFV6C18Z9
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,888,698
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Description
- Abstract
- Intestinal epithelium is the fastest dividing tissue in the body, and the health of the cells can be easily impacted by environmental toxins and drugs. This organ system is therefore a prime target for biological testing of medicinal compounds, prebiotics, and microbial products. An in vitro GUT model that can precisely predict these impacts will reduce the burden of testing by diminishing reliance on animal models, minimizing the number of overlapping assessments and helping to eliminate unnecessary testing. To meet this need, altis biosystems INC., an early stage biotechnology company, will collaborate with scientists at university of washington to develop a novel 2-dimensional (2D) crypt platform that emulates the GUT epithelium. Human primary intestinal epithelial stem cells will be patterned on the platform to mimic a GUT epithelium possessing a stem-cell niche, and migratory proliferating and differentiating cells. This planar 2D platform will enable high-content/high-throughput assays in a rugged and reproducible manner. In this phase II sbir, this collaboration will generate a commercial 2D crypts organ-on-a-chip platform using established 12-well plates and expand the platform to incorporate a 96-well plate high-content format. In addition, the commercial platform will be benchmarked in collaboration with astrazeneca's oncology safety team as a predictive assay system for intestinal off-target effects
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $900,267 | |
| Original award | $988,431 |
Quick answers
Who received award R44DK130647?
R44DK130647 was awarded to Altis Biosystems, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 22, 2022.
How much is award R44DK130647 worth?
$1,888,698 has been obligated on R44DK130647.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award